GlassScriptPhysician profile
Crystal Pawula
NPI 1184092546
$5,876.54
in general payments reported to CMS, 2019-2025
30 companies · $945 in 2025
The $945 reported for 2025 was more than what 84% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $750 · 2022: $1,822 · 2023: $1,498 · 2024: $863 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,304.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $698.07 | 2021-2024 | Coroflow, Mitraclip, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $697.79 | 2021-2025 | Lifevest |
| Amgen INC. | $662.30 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $591.30 | 2021-2025 | Watchman Access System, Latitude Communicator Power Supply |
| E.R. Squibb & Sons, L.L.C. | $497.32 | 2021-2025 | Eliquis, Camzyos |
| Cvrx, INC. | $424.05 | 2022-2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $300.06 | 2022-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $248.67 | 2021-2025 | Verquvo |
| Medtronic, INC. | $231.23 | 2021-2024 | Linq II |
| Bayer Healthcare Pharmaceuticals INC. | $199.05 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.39 | 2022-2024 | Jardiance |
| Silk Road Medical, INC. | $145.84 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Novo Nordisk INC | $143.05 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $131.71 | 2021-2023 | Xarelto |
| Pulmonx Corporation | $110.45 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $104.60 | 2022-2025 | |
| Pfizer INC. | $101.28 | 2022-2025 | |
| Inari Medical, INC. | $84.62 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $71.82 | 2022 | |
| Atricure, INC. | $66.36 | 2024 | |
| Philips North America LLC | $38.82 | 2022-2023 | |
| Kite Pharma, INC. | $31.20 | 2025 | Yescarta |
| Glaxosmithkline, LLC. | $24.86 | 2025 | Zejula, Jemperli |
| Amarin Pharma, INC. | $21.32 | 2022 | |
| Impulse Dynamics (USA) INC. | $18.61 | 2024 | Optimizer |
| Angiodynamics, INC. | $18.27 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.21 | 2025 | Evkeeza |
| Takeda Pharmaceuticals U.S.A., INC. | $15.11 | 2025 | Ninlaro |
| Sanofi-Aventis U.S. LLC | $13.68 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Pawula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.